Login / Signup

Naltrexone and Its Noroxymorphone Minor Metabolite - A Case Report.

Cornel N StanciuSamantha Gnanasegaram
Published in: Journal of psychoactive drugs (2019)
As part of substance use maintenance programs, individuals are monitored for sobriety through urine drug screens. A positive screen, and its confirmation and interpretation, can have devastating consequences, sometimes even leading to termination from the program and relapse. Naltrexone metabolism involves several steps and metabolites - one minor metabolite with very little mention in medical literature being noroxymorphone. This is also the final intermediate in the metabolic pathway of oxycodone; hence, detection is naturally presumed by clinicians to be attributed to oxycodone use. Through this case report, we alert clinicians that, depending on individual pharmacogenomics, it is possible to obtain a positive confirmation of this component alone (without any oxycodone pathway intermediates) with naltrexone administration.
Keyphrases
  • case report
  • alcohol use disorder
  • high throughput
  • palliative care
  • systematic review
  • clinical decision support
  • public health
  • ms ms
  • quality improvement
  • adverse drug
  • genome wide
  • free survival
  • real time pcr